Akorn Reports ANDA Approval For Bimatoprost Ophthalmic Solution - Quick Facts

(RTTNews) - Akorn, Inc. (AKRX) announced it has received a new Abbreviated New Drug Application (ANDA) approval from the U.S. FDA for Bimatoprost Ophthalmic Solution, 0.03%. Bimatoprost ophthalmic solution, 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.

Akorn noted that, according to IQVIA, sales of bimatoprost ophthalmic solution, 0.03% were approximately $63.5 million for the twelve months ended August 2018.

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals.